Adipotide (FTPP) 10 mg

Peptide Hubs Adipotide (FTPP)

Adipotide, also known as FTPP (Fat-Targeted Proapoptotic Peptide), represents a targeted research peptide designed for investigative use in metabolic and body composition studies. This lyophilized powder comes in a 10 mg vial, with third-party lab verification confirming a potency of 10.49 mg, ensuring researchers receive a precisely dosed and high-quality product. For bodybuilders, athletes, and fitness enthusiasts engaged in advanced research, Adipotide offers a unique mechanism of action by targeting the blood supply to white adipose tissue, making it a compound of significant interest in cutting-phase protocols.

Adipotide (FTPP) Composition

Each vial contains 10 mg of the synthetic peptide Adipotide (FTPP) as a sterile, lyophilized powder. The peptide sequence is designed to bind to a protein on the surface of blood vessels that supply white fat cells, initiating a targeted process. The product contains no fillers or preservatives, and it requires reconstitution with bacteriostatic water before use in a research setting.

Bodybuilding and Fitness Research Benefits

In research models, Adipotide has shown potential for influencing body composition by targeting stubborn fat deposits. For athletes and bodybuilders, its primary investigational benefits include the potential reduction of visceral and subcutaneous adipose tissue without systemic catabolic effects on muscle. This makes it a subject of interest for achieving ultra-lean, defined physiques, particularly when diet and exercise plateau. Research suggests it may help in targeting specific problem areas that are traditionally resistant to fat loss.

Therapeutic and Research Indication

While primarily a research chemical, Adipotide's mechanism has been studied in preclinical models for obesity and related metabolic conditions. Its action involves binding to prohibitin, a protein expressed on the surface of endothelial cells in white adipose tissue vasculature, and inducing apoptosis (cell death) in those blood vessels. This cuts off the nutrient supply to fat cells, leading to their reduction. It's crucial to note that authoritative sources like the National Institutes of Health (NIH) have published on its mechanism, underscoring its role as a serious research tool, not a consumer supplement.

Dosage for Research (Men)

Research dosage protocols for Adipotide are not standardized for human use, as it remains an investigational peptide. Preclinical studies have used specific dosing schedules based on body weight. Researchers must consult published literature and establish strict, minimal-dose protocols. A common approach in research settings involves a carefully calculated microgram-per-kilogram dose, administered via subcutaneous injection. Cycles are typically short-term due to the peptide's potent mechanism. Starting at the lowest possible research dose is paramount.

Dosage for Research (Women)

Due to the potent and targeted nature of Adipotide, extreme caution is advised in any research involving female subjects. Hormonal fluctuations can influence fat distribution and metabolism, potentially altering the response. Dosing in research models is typically weight-based, and any protocol must be even more conservative than those considered for male subjects. Comprehensive understanding of its localized effects is required before any investigative use.

Active Life

The active life of Adipotide after administration in research models is relatively short, often estimated at several hours. However, its biological *effects* on adipose tissue vasculature are cumulative and may manifest over days following a cycle of administration. The peptide is typically cleared from the systemic circulation rapidly, but the induced changes in fat tissue are longer-lasting.

Adipotide (FTPP) Side Effects

In research models, observed effects have included increased urination and thirst due to kidney tissue expressing a similar target protein. This underscores the importance of targeted research and monitoring kidney function parameters. Other potential research side effects can include temporary fatigue and minor irritation at the injection site. Its targeted action means side effects are related to its mechanism and require careful observation.

Contraindications and Precautionary Measures

Adipotide is contraindicated in research involving subjects with pre-existing kidney conditions or impairment. It should not be used in conjunction with other compounds that stress renal function. Researchers must ensure subjects are well-hydrated. A full review of the subject's health status is mandatory prior to consideration in any study. It is for research purposes only and not for human consumption or therapeutic use.

Overdosage in Research

Exceeding research-level dosages drastically increases the risk of adverse effects, particularly renal toxicity. Symptoms of overdosage in models include severe dehydration and acute kidney stress. In a research context, immediate cessation and supportive measures focused on hydration and electrolyte balance are critical. It highlights the necessity of precise dosing and rigorous research protocols.

Adipotide (FTPP) Stack/Cycle for Research

In investigative body composition studies, Adipotide is often researched in a "cutting" context. It may be stacked with other research peptides that support fat metabolism or preserve lean mass, but extreme caution is required to avoid synergistic toxicity. Potential research stacks could include:

• AOD 9604 for its potential fragment hormone-like activity on fat metabolism.
• Tesamorelin to investigate combined effects on visceral adipose tissue.
• GHRP-6 to potentially support hunger modulation and growth hormone release during a caloric deficit.
• BPC 157 for its potential supportive role in systemic healing and recovery, though not concurrently with Adipotide's active cycle.
• Melanotan 2 for its independent effects on appetite and fat metabolism in some research models.

All stacks are hypothetical and for advanced research design only.

Package Presentation

The product is supplied as one sterile glass vial containing 10 mg of Adipotide (FTPP) as a white lyophilized powder. The vial is sealed and shipped with a protective cap. Each shipment is discreet and secure.

Storage

Store the lyophilized powder in a cool, dry place, away from direct light. For long-term stability, store at or below -20°C (-4°F). After reconstitution with bacteriostatic water, the solution should be refrigerated at 2-8°C (36-46°F) and used within a short timeframe as per sterile research guidelines.

Adipotide (FTPP) Referrers

The mechanism of Adipotide has been documented in scientific literature. Key referrers include studies published through the NIH's PubMed database, which detail its proapoptotic effect on white adipose tissue vasculature. These resources are essential for any researcher to understand the compound's history, mechanism, and potential implications fully.

Third-Party Lab Test

2025-11-26

View Result

10.49 mg